Symbol
| SLC2A3
| contributors: np/mct - updated : 19-05-2015
|
HGNC name
| solute carrier family 2 (facilitated glucose transporter), member 3
|
HGNC id
| 11007
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
| amplification
|  
|  
|
SLC2A3 duplication might serve as a genetic modifier of CHDs and/or aortic arch anomalies in individuals with del22q11 | constitutional
|  
|  
| --over
|  
|
in human pregnancies complicated by late-onset intrauterine growth restriction | constitutional
|  
|  
| --low
|  
|
in Alzheimer Disease brain and correlates with tau pathology | |
Susceptibility
|
to myelomeningocele |
Variant & Polymorphism
SNP
| involving the SLC2A3 gene may be associated with increased susceptibility to myelomeningocele |
|
|
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | | | |
may be a potential target for therapy against cancers caused by the aberrantly activated MTOR signaling |
| | | |
| homozygous null deletion of Slc2a3 is embryonic lethal in mice and the heterozygous deletion is not lethal but results in intrauterine growth retardation |